The data comes from a second Phase III trial of Quad, a fixed-dose, single-tablet regimen made up of Gilead’s investigational drugs elvitegravir and cobicistat combined with the two active ingredients in Truvada (emtricitabine and tenofovir). The study compared Quad with ritonavir-boosted atazanavir plus Truvada.